TITLE

HEALTH CANADA APPROVES NOVARTIS ORAL CANCER DRUG

PUB. DATE
November 2001
SOURCE
Worldwide Biotech;Nov2001, Vol. 13 Issue 11, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the approval of an oral therapy for the treatment of chronic myeloid leukemia from Novartis Pharmaceuticals Canada Inc. by Health Canada in 2001.
ACCESSION #
5457845

 

Related Articles

  • Aclasta indications.  // Australian Journal of Pharmacy;Oct2009, Vol. 90 Issue 1073, p36 

    The article evaluates the Aclasta injection solution from Novartis Pharmaceuticals Canada Inc.

  • New warnings of renal dysfunction associated with Aclasta.  // Reactions Weekly;10/23/2010, Issue 1324, p3 

    The article discusses the Dear Health Care Professional letter and a Public Communication by Novartis Pharmaceuticals Canada, in collaboration with Health Canada, informing the public about revisions made to the Aclasta Product Monograph concerning the risk of adverse renal reactions linked with...

  • News @ a glance.  // CMAJ: Canadian Medical Association Journal;10/9/2007, Vol. 177 Issue 8, p846 

    The article offers local news briefs related to health in Canada. Australian authorities decided to yank lumiracoxib of Novartis Pharmaceuticals Canada Inc. from the market after reports of liver problems. Meanwhile, the Canadian Institutes of Health Research has adopted a policy that will...

  • Regulatory & Healthcare News.  // PharmacoEconomics & Outcomes News;7/12/2008, Issue 557, p10 

    This section offers news briefs on the pharmaceutical industry as of July 12, 2008. Novartis has disclosed that its zoledronic acid will not be reimbursed in Canada. A report by Decision Resources has predicted market growth for renal cell carcinoma drugs by 2018. Novartis Canada has reported...

  • MARKETPLACE.  // Oncology Exchange;Aug2011, Vol. 10 Issue 3, p48 

    The article offers world news briefs to the marketing of oncology drugs or indications in the U.S. and Canada. It states that Canada has approved the Tasigna drug from Novartis Pharmaceuticals Canada Inc. for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive...

  • Reduced Zometa dosing and new Aclasta label in Canada.  // Reactions Weekly;8/20/2005, Issue 1065, p2 

    Reports on the changes to the Zometa dosing information made to minimise the risk of renal dysfunction released by Novartis Pharmaceuticals Canada in collaboration with Health Canada. Elimination of the recommended Zometa dose for the retreatment of tumour-induced hypercalcaemia; Link between...

  • Untitled.  // Reactions Weekly;10/13/2007, Issue 1173, p1 

    The article reports that Health Canada has revoked the marketing permit for Prexige, a brand of lumiracoxib, due to health risks. After receiving the data submitted by Novartis Pharmaceuticals Canada, the drug's manufacturer, Health Canada concluded that liver-related adverse events associated...

  • Myeloid leukemia after hematotoxins. Larson, Richard A.; LeBeau, Michelle M. // Environmental Health Perspectives Supplements;Dec96 Supplement 6, Vol. 104, p1303 

    Investigates myeloid leukemia after hematotoxins. Mutations and leukemogenesis; Prior therapy, latency period and clinical features of therapy-related myeloid leukemia; Role of 11q23 translocations; Cytogenetic abnormalities in therapy-related myeloid leukemia.

  • Chronic myeloid leukaemia. Goldman, John // BMJ: British Medical Journal (International Edition);03/01/97, Vol. 314 Issue 7081, p657 

    Focuses on chronic myeloid leukemia. Clinical features; Survival from date of diagnosis; Chronic phase disease; Peripheral blood findings; Recommendation of cryopreservation of semen to young men; Treatment.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics